What is the recommended duration of Eliquis (apixaban) therapy for a leg deep‑vein thrombosis (DVT)?

Duration of Eliquis (Apixaban) Therapy for Leg DVT

For a leg DVT, treat with Eliquis for a minimum of 3 months, then determine if extended therapy (no scheduled stop date) is warranted based on whether the DVT was provoked or unprovoked and the patient's bleeding risk.

Initial Treatment Phase

Start with Eliquis 10 mg twice daily for 7 days, then reduce to 5 mg twice daily for the remainder of treatment 1. This dosing applies regardless of DVT location (proximal or distal).

Duration Based on Clinical Scenario

Provoked DVT (Surgery or Transient Risk Factor)

• Surgery-provoked DVT: Treat for exactly 3 months and stop 2

  • Strong recommendation (Grade 1B) against shorter duration, longer time-limited periods (6-12 months), or extended therapy
  • The surgical provocation eliminates ongoing VTE risk once healed

• Nonsurgical transient risk factor (trauma, immobilization, estrogen): Treat for 3 months 2

  • If low or moderate bleeding risk: Consider stopping at 3 months (Grade 2B)
  • If high bleeding risk: Definitely stop at 3 months (Grade 1B)
  • Recent evidence suggests patients with enduring risk factors alongside the transient trigger may benefit from extended therapy 3

Unprovoked DVT (No Clear Provoking Factor)

After completing at least 3 months of treatment, reassess for extended therapy 2:

First unprovoked proximal DVT:

• Low or moderate bleeding risk: Extended therapy is suggested over stopping (Grade 2B) 2
• High bleeding risk: Stop at 3 months (Grade 1B)

First unprovoked distal DVT:

• Low or moderate bleeding risk: Stop at 3 months (Grade 2B)
• High bleeding risk: Stop at 3 months (Grade 1B)

Second unprovoked VTE:

• Low bleeding risk: Extended therapy is strongly recommended (Grade 1B) 2
• Moderate bleeding risk: Extended therapy is suggested (Grade 2B)
• High bleeding risk: Consider stopping at 3 months (Grade 2B)

Cancer-Associated DVT

• Not high bleeding risk: Extended therapy strongly recommended (Grade 1B) 2
• High bleeding risk: Extended therapy still suggested (Grade 2B)
• Note: LMWH is preferred over apixaban for cancer-associated thrombosis (Grade 2C) 2, though recent data suggest apixaban may be acceptable in selected cases 4

Extended Therapy Dosing

For patients continuing beyond 6 months, reduce to apixaban 2.5 mg twice daily 1. This lower dose maintains efficacy for secondary prevention with potentially less bleeding risk 5.

Key Decision Points

Bleeding Risk Stratification:

• High risk: Active bleeding, recent major bleeding, severe thrombocytopenia, severe liver disease
• Moderate risk: Age >75, prior bleeding history, concurrent antiplatelet therapy, renal impairment
• Low risk: None of the above

Factors Favoring Extended Therapy:

• Male sex (higher recurrence risk than females)
• Elevated D-dimer 1 month after stopping anticoagulation
• Extensive thrombosis at presentation
• Unprovoked presentation
• Second VTE event

Common Pitfalls

1. Don't automatically extend all unprovoked DVTs: Bleeding risk must be carefully weighed, especially in elderly patients or those on antiplatelet therapy

2. Reassess annually: Extended therapy means "no scheduled stop date," but requires periodic reassessment (at least yearly) 2

3. Don't use full-dose apixaban indefinitely: After 6 months, switch to 2.5 mg twice daily for extended prevention 1

4. Distal DVT considerations: Not all isolated distal DVTs require anticoagulation; if treated, duration follows the same principles but with lower threshold for stopping at 3 months 2

5. Provoked with enduring factors: Recent evidence suggests patients with both transient provoking factors AND enduring risk factors (obesity, chronic immobility, active cancer) may benefit from extended therapy despite the "provoked" classification 3